Dipyridamole Tablets

It has anti-thrombotic effect. Dipyridamole inhibits platelet aggregation, and high concentrations (50mu;g/ml) can inhibit platelet release. The mechanism of action may be: 1. Inhibit the uptake of adenosine by platelets, epithelial cells and erythrocytes. The inhibitory effect is dose-dependent at therapeutic concentrations (0.5-1.9mu;g/dl). The local adenosine concentration increases, acting on the A2 receptors of platelets, stimulating adenylate cyclase, and increasing cyclic adenosine monophosphate (cAMP) in platelets. Through this pathway, platelet aggregation caused by stimulation such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP) is inhibited. 2. Inhibit phosphodiesterase (PDE) in various tissues. The therapeutic concentration inhibits cyclic guanosine monophosphate phosphodiesterase (cGMP-PDE), and the inhibitory effect on cAMP-PDE is weak, thereby enhancing the increase in cGMP concentration caused by endothelial relaxing factor (EDRF). 3. Inhibit the formation of thromboxane A2 (TXA2), which is a strong agonist of platelet activity. 4. Enhance the effect of endogenous PGI2. Dipyridamole has a vasodilatory effect. Dogs given 0.5-4.0 mg/kg of dipyridamole via the duodenum produced a dose-related decrease in systemic and coronary vascular resistance, a decrease in systemic blood pressure, and an increase in coronary blood flow. It takes effect 24 minutes after administration and lasts for about 3 hours. The same hemodynamic effects are observed in humans. However, acute intravenous administration can reduce local myocardial perfusion at the distal end of the stenotic coronary artery. The results of the mutagenicity test were negative. Rat reproduction tests used 60 times the maximum recommended daily dose of dipyridamole for humans and showed no evidence of reproductive damage. However, at 115 times the maximum recommended daily dose for humans, the number of corpora lutea was significantly reduced and live fetal implantation was reduced. Tests on mice, rats, and rabbits did not show evidence that dipyridamole harmed the fetus. The oral LD50 for mice is 2150 mg/kg; the single oral lethal dose is 6000 mg/kg in rats and 350 mg/kg in dogs.

The main ingredient of this product is dipyridamole.

Film-coated tablets.

Used for thromboembolic diseases and ischemic heart disease.

Oral administration: 25-50 mg each time, 3 times a day, before meals. Or as directed by a doctor.

Adverse reactions are mild and short-lived at therapeutic doses. The initial side effects usually disappear after long-term use. Common adverse reactions include dizziness, headache, vomiting, diarrhea, flushing, rash and itching. Angina pectoris and liver dysfunction are rare. It is rare for adverse reactions to persist or be intolerable, which can be eliminated after drug withdrawal. Rare adverse reactions reported in post-marketing experience include laryngeal edema, fatigue, discomfort, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis alopecia, cholelithiasis, palpitations and tachycardia.

Contraindicated for allergy sufferers.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. It has a synergistic effect with aspirin. When used in combination with aspirin, the dosage can be reduced to 100-200 mg per day. 2. When this product is used together with dicoumarol anticoagulants, bleeding does not increase or worsen.

Keep in a light-proof and airtight container.

25mg

24 months.

Shanghai Meiyou Pharmaceutical Co., Ltd.

• Founded in:

  1998-02-26

• Address:

  No. 1388, Wusi Road, Fengxian District, Shanghai

• Tax NO.:

  91310120134051612H

• Registered Funds:

  64.8 million yuan

• Email:

  Log in to view